Compounds > 4-fluorodeprenyl
Page last updated: 2024-12-07

4-fluorodeprenyl

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-fluorodeprenyl: structure given in first source; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID128418
CHEMBL ID64741
SCHEMBL ID4549815
MeSH IDM0178323

Synonyms (17)

Synonym
4-fluorodeprenyl
CHEMBL64741
1-(4-fluorophenyl)-n-methyl-n-prop-2-ynylpropan-2-amine
unii-pv4shr2l8j
(s)-(+)-4-fluorodeprenyl
(r)-(-)-4-fluorodeprenyl
pv4shr2l8j ,
benzeneethanamine, 4-fluoro-n,alpha-dimethyl-n-2-propynyl-
103596-43-6
SCHEMBL4549815
DTXSID50874435
4-fluoro-n,alpha-dimethyl-n-2-propynyl-benzeneethanamine
PD159660
4f-deprenyl
p-fluorodeprenyl
n-[1-(4-fluorophenyl)propan-2-yl]-n-methylprop-2-yn-1-amine
4-fluoro-n,alpha-dimethyl-n-2-propyn-1-ylbenzeneethanamine
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID7960The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis of (R)-(-)- and (S)-(+)-4-fluorodeprenyl and (R)-(-)- and (S)-(+)-[N-11C-methyl]-4-fluorodeprenyl and positron emission tomography studies in baboon brain.
AID7957Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis of (R)-(-)- and (S)-(+)-4-fluorodeprenyl and (R)-(-)- and (S)-(+)-[N-11C-methyl]-4-fluorodeprenyl and positron emission tomography studies in baboon brain.
AID7958Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis of (R)-(-)- and (S)-(+)-4-fluorodeprenyl and (R)-(-)- and (S)-(+)-[N-11C-methyl]-4-fluorodeprenyl and positron emission tomography studies in baboon brain.
AID7963The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis of (R)-(-)- and (S)-(+)-4-fluorodeprenyl and (R)-(-)- and (S)-(+)-[N-11C-methyl]-4-fluorodeprenyl and positron emission tomography studies in baboon brain.
AID7961The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis of (R)-(-)- and (S)-(+)-4-fluorodeprenyl and (R)-(-)- and (S)-(+)-[N-11C-methyl]-4-fluorodeprenyl and positron emission tomography studies in baboon brain.
AID7959The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis of (R)-(-)- and (S)-(+)-4-fluorodeprenyl and (R)-(-)- and (S)-(+)-[N-11C-methyl]-4-fluorodeprenyl and positron emission tomography studies in baboon brain.
AID7962The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis of (R)-(-)- and (S)-(+)-4-fluorodeprenyl and (R)-(-)- and (S)-(+)-[N-11C-methyl]-4-fluorodeprenyl and positron emission tomography studies in baboon brain.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (77.78)18.2507
2000's0 (0.00)29.6817
2010's2 (22.22)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.92 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
amphetamine
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.		1.9910primary amine
methamphetamine
Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.		1.9910amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic
selegiline
Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.		4.790selegiline;
terminal acetylenic compound		geroprotector
mofegiline
[no description available]		1.9810
ConditionIndicatedRelationship StrengthStudiesTrials
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		01.9910
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		01.9810